PT  - JOURNAL ARTICLE
AU  - Darren S. Thomas
AU  - Alasdair N Warwick
AU  - Abraham Olvera-Barrios
AU  - Catherine Egan
AU  - Roy Schwartz
AU  - Sudeshna Patra
AU  - Haralabos Eleftheriadis
AU  - Anthony P. Khawaja
AU  - Andrew Lotery
AU  - Philipp L. Müeller
AU  - Robin Hamilton
AU  - Ella Preston
AU  - Paul Taylor
AU  - Adnan Tufail
AU  - UK EMR Users Group
TI  - Estimating excess visual loss in people with neovascular age-related macular degeneration during the COVID-19 pandemic
AID  - 10.1101/2020.06.02.20120642
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.02.20120642
4099  - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20120642.short
4100  - http://medrxiv.org/content/early/2020/06/05/2020.06.02.20120642.full
AB  - Objectives To report the reduction in new neovascular age-related macular degeneration (nAMD) referrals during the COVID-19 pandemic and estimate the impact of delayed treatment on visual outcomes at one year.Design Retrospective clinical audit and simulation model.Setting Multiple UK NHS ophthalmology centres.Participants Data on the reduction in new nAMD referrals was obtained from four NHS Trusts in England comparing April 2020 to April 2019. To estimate the potential impact on one-year visual outcomes, a stratified bootstrap simulation model was developed drawing on an electronic medical records dataset of 20,825 nAMD eyes from 27 NHS Trusts.Main outcome measures Simulated mean visual acuity and proportions of eyes with vision ≤6/60, ≤6/24 and ≥6/12 at one year under four hypothetical scenarios: no treatment delay, 3, 6 and 9-month treatment delays. Estimated additional number of eyes with vision ≤6/60 at one year nationally.Results The number of nAMD referrals at four major eye treatment hospital groups based in England dropped on average by 72% (range 65 to 87%) in April 2020 compared to April 2019. Simulated one-year visual outcomes for 1000 nAMD eyes with a 3-month treatment delay suggested an increase in the proportion of eyes with vision ≤6/60 from 15.5% (13.2 to 17.9) to 23.3% (20.7 to25.9), and a decrease in the proportion of eyes with vision ≥6/12 (driving vision) from 35.1% (32.1 to 38.1) to 26.4% (23.8 to29.2). Outcomes worsened incrementally with longer modelled delays. Assuming nAMD referrals are reduced to this level at the national level for only one month, these simulated results suggest an additional 186-365 eyes with vision ≤6/60 at one-year with even a short treatment delay.Conclusions We report a large decrease in nAMD referrals during the first month of COVID-19 lockdown and provide an important public health message regarding the risk of delayed treatment. As a conservative estimate, a treatment delay of 3 months could lead to a >50% relative increase in the number of eyes with vision ≤6/60 and 25% relative decrease in the number of eyes with driving vision at one year.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAT, CE, RS received a proportion of their funding from the Department of Healths NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health. AW is supported by the UCL Wellcome Trust PhD Programme for Clinicians. PLM is supported by the German Research Foundation (grant # MU4279/2-1). Data collection was funded by a Grant from Novartis Pharmaceutical. Novartis has no input into the analysis, interpretation or content of this manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was not required for the analysis of anonymised EMR data. Signed permission was returned from the lead clinician and Caldicott guardian (who oversees data protection) at each clinical site allowing anonymized data to be extracted. The study is registered on a list of studies using anonymised data at the lead clinicians home institution.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability statement. All analysis code is available